Development of a selective and highly sensitive fluorescence assay for nucleoside triphosphate diphosphohydrolase1 (NTPDase1, CD39)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Development of a selective and highly sensitive fluorescence assay for nucleoside triphosphate diphosphohydrolase1 (NTPDase1, CD39)

Published:2018 Issue:22 Volume:143 Page:5417-5430
ISSN:0003-2654
Container-title:The Analyst
language:en
Short-container-title:Analyst

Author:

Lee Sang-Yong¹²³⁴⁵^ORCID,Luo Xihuan¹²³⁴⁵,Namasivayam Vigneshwaran¹²³⁴⁵^ORCID,Geiss Jennifer¹²³⁴⁵,Mirza Salahuddin¹²³⁴⁵,Pelletier Julie⁶⁷⁸,Stephan Holger⁹¹⁰¹¹¹²^ORCID,Sévigny Jean⁶⁷⁸¹³¹⁴^ORCID,Müller Christa E.¹²³⁴⁵^ORCID

Affiliation:

1. PharmaCenter Bonn

2. Pharmaceutical Institute

3. Pharmaceutical Chemistry I

4. University of Bonn

5. D-53121 Bonn

6. Centre de Recherche du CHU de Québec – Université Laval

7. Québec City

8. Canada

9. Institute of Radiopharmaceutical Cancer Research

10. Helmholtz-Zentrum Dresden - Rossendorf

11. 01328 Dresden

12. Germany

13. Départment de Microbiologie-Infectiologie et d'Immunologie

14. Faculté de Médecine

Abstract

A new fluorescence-based assay is useful for monitoring CD39 reactions and enables low picomolar detection of nucleotides.

Funder

Canadian Institutes of Health Research

Fonds de Recherche du Québec - Santé

Natural Sciences and Engineering Research Council of Canada

Deutsche Forschungsgemeinschaft

Publisher

Royal Society of Chemistry (RSC)

Subject

Electrochemistry,Spectroscopy,Environmental Chemistry,Biochemistry,Analytical Chemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2018/AN/C8AN01108G

Reference51 articles.

1. Cellular function and molecular structure of ecto-nucleotidases

2. Extracellular metabolism of ATP and other nucleotides

3. Impact of Ectoenzymes on P2 and P1 Receptor Signaling

4. Generation and Characterization of Specific Antibodies to the Murine and Human Ectonucleotidase NTPDase8

5. ENTPD1/CD39 is a promising therapeutic target in oncology

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Protein kinase inhibitor ceritinib blocks ectonucleotidase CD39 – a promising target for cancer immunotherapy;Journal for ImmunoTherapy of Cancer;2022-08

2. 2‐Substituted thienotetrahydropyridine derivatives: Allosteric ectonucleotidase inhibitors;Archiv der Pharmazie;2021-10-26

3. Identification of Novel CD39 Inhibitors Based on Virtual Screening and Enzymatic Assays;Journal of Chemical Information and Modeling;2021-10-14

4. Nucleotide Analog ARL67156 as a Lead Structure for the Development of CD39 and Dual CD39/CD73 Ectonucleotidase Inhibitors;Frontiers in Pharmacology;2020-09-08

5. Development of Anthraquinone Derivatives as Ectonucleoside Triphosphate Diphosphohydrolase (NTPDase) Inhibitors With Selectivity for NTPDase2 and NTPDase3;Frontiers in Pharmacology;2020-08-27

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3